Business Wire

EUNETWORKS

22.4.2024 09:01:28 CEST | Business Wire | Press release

Share
euNetworks Adds a New High-Density Fibre Network in Brussels

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced the addition of a new duct and fibre-based network in Brussels to its Pan-European network footprint. This new addition takes the company’s owned and operated metropolitan network count to 18 in Europe. This is the latest of the company’s investments in digital infrastructure in the Benelux region, following the addition of a duct-based fibre network in Belgium through acquisition in April 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422857344/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

euNetworks' Metropolitan Network in Brussels, Belgium. (Graphic: Business Wire)

Last year, the 1,660 kilometres of fibre network acquired added unique routes in Brussels and long haul routes across Belgium, delivering a solid complement to euNetworks’ in-place network in the region. It also presented compelling additional investment opportunities for euNetworks in the long haul, in adjacent geographies and in building a new Brussels city network to give customers a truly end-to-end experience.

Since then, euNetworks has invested further in the Brussels metropolitan area, overbuilding acquired duct, purchasing additional cable and duct, and building additional high fibre count connectivity and diversity between key data centre sites, clusters and network aggregation points to deliver this new Brussels footprint.

Brussels Metro:

  • 41 kilometres of duct and high-fibre count network
  • Connects 5 data centres day 1, including LCL Brussels-North, Digital Realty BRU1, BRU3 & BRU4, AtlasEdge Brussels BRU001
  • With multiple, diverse entry points to these on-net data centres
  • Additional data centres are in the pipeline to be connected to support customer demand
  • Dark Fibre, Long Haul and Metro Wavelengths and Ethernet-based services are available across this footprint, with four diverse 100G Ethernet nodes to be installed, delivering resiliency and redundancy
  • Seamless connectivity between Brussels connected data centres and other regional data centre clusters and hubs in Ghent, Antwerp, Charleroi and Saint Ghislain
  • With multiple diverse long haul connectivity options from Brussels

“Belgium is a growing digital hub, with significant investment in the region to support emerging technology trends such as IoT and GenAI, which drive Cloud adoption and strategies,” said Paula Cogan, Chief Executive Officer of euNetworks. “Our Brussels and wider Belgium investments strengthen our leadership in European critical infrastructure as we focus on the ongoing densification of the high-bandwidth demand region of FLAP (Frankfurt, London, Amsterdam and Paris). We continue our approach to deliver a differentiated proposition to the market, offering unique and scalable network routes to our customers between key data centres. We also have a strong pipeline of ongoing investment to continue to support their growing bandwidth needs, further capitalising on the investment we made last year. I’m very proud of what the team have accomplished in a relatively short timeframe, delivering our eighteenth metro network to market. We’ve also expanded our local operations and sales presence, enabling strong support for our customers locally as they move forward with their infrastructure investments.”

euNetworks builds and invests in city and long haul fibre networks to connect key European data centres and data hubs. The company owns and operates deep fibre networks in 18 cities as well as a highly differentiated long haul network that spans 45,000 route kilometres across 17 countries. As a specialist in the sector, euNetworks continues to grow and invest in partnership with its customers, investing in new technologies and deepening its unique fibre network in Europe.

About euNetworks

euNetworks is a critical bandwidth infrastructure company, owning and operating 18 fibre-based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 536 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs.

The company delivers services with an active commitment to sustainability and is focused on its path to being carbon emissions net zero, environmentally responsible supply chain management and working as a community and industry to collaborate on the environmental challenges ahead. For further information visit eunetworks.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422857344/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye